Advanced searches left 3/3

Methotrexate Chemotherapy - Crossref

Summarized by Plex Scholar
Last Updated: 02 May 2022

* If you want to update the article please login/register

Intraneoplastic injection of methotrexate for experimental brain-tumor chemotherapy

Following intracerebral injection of MTX- 3 H in nontumor-bearing animals, a significant amount of the drug was retained in the head, more than could have been retained after systemic administration, and rapid spread of the disease throughout the ipsilateral hemisphere. Intraneoplastic injection may have advantages for brain tumor therapy, even though the drug delivery in the intracerebral tumors was not uniform and some intracranial tumor deposits contained less radioactivity than areas closer to the site of injection.

Source link: https://doi.org/10.3171/jns.1977.46.2.0165


Preirradiation chemotherapy including “eight drugs in 1 day” regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study

The aim of this review was to determine the safety and effectiveness of a drug strategy that includes "sandwich" chemotherapy, i. e. chemotherapy alternated with radiotherapy, and reduced doses of supratentorial radiation in children with medulloblastoma. In this prospective nonrandomized study, 70 percent of patients with newly diagnosed medulloblastoma from eight centers were treated between March 1985 and September 1988. Patients in Group B were included in those that did not fit the requirements for Group A. A total of 68 children was selected, with 31 in Group A and 37 in Group B, and 37 in Group B, after surgery in Group A and Group B's 5th week. The median radiation dose to the posterior fossa, the spinal axis, and the brain was 54 Gy, 36 Gy, and 27 Gy, respectively, in patients older than two years. With four 8/1 courses per month, Group B patients received postirradiation chemotherapy. The median time from surgery to radiation therapy was 50 days. On Day 102, one fatality due to chicken pox was reported, and one World Health Organization Grade IV infection occurred. These were 74% and 62% in Group A, and 57% and 57% in Group B. Patients with metastasis had a non-significant risk of a worse prognosis than those with nonmetastatic disease. The 7-year DFS prevalence for children who were more or less than 30 Gy to the brain in Group B were 69% and 52% respectively.

Source link: https://doi.org/10.3171/jns.1995.82.4.0608


Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome

The administration of primary central nervous system lymphoma with chemotherapy prior to whole-brain radiation therapy has improved outcomes in this previously lethal disease. In 12 of the 13 patients who were initially diagnosed, complete or partial responses to intravenous methotrexate were seen in 12 of 13 patients. Prior to WBRT, 25 patients have now been treated with one to six cycles of methotrexate every 10 to 21 days.

Source link: https://doi.org/10.3171/jns.1994.81.2.0188

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions